Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial.
Priya RastogiHanna BandosPeter C LucasLaura van 't VeerJia-Perng J WeiCharles E GeyerLouis FehrenbacherStephen K L ChiaAdam M BrufskyJanice M WalsheGamini S SooriShaker R DakhilSoonmyung PaikSandra M SwainAndrea R MenicucciM William AudehNorman WolmarkEleftherios P P MamounasPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
The primary hypothesis of predictive ability of MP on DR was not confirmed. However, the secondary outcomes demonstrated MP was predictive of ELT response and identified a subset of patients with early-stage hormone receptor-positive BC (MP-LR) with improved outcomes from ELT. These data could have important clinical implications in patient selection beyond clinical risk assessment for EET.
Keyphrases
- early stage
- risk assessment
- palliative care
- case report
- study protocol
- high throughput
- electronic health record
- genome wide
- copy number
- polycystic ovary syndrome
- editorial comment
- stem cells
- sentinel lymph node
- gene expression
- metabolic syndrome
- radiation therapy
- dna methylation
- bone marrow
- genome wide identification
- adipose tissue
- skeletal muscle
- transcription factor